StockNews.com Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Strong-Buy

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a note issued to investors on Wednesday.

A number of other equities analysts also recently commented on REGN. Royal Bank of Canada lifted their price target on Regeneron Pharmaceuticals from $1,252.00 to $1,260.00 and gave the stock an “outperform” rating in a research note on Friday, October 4th. TD Cowen lifted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Barclays lifted their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Piper Sandler lifted their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Finally, Leerink Partners reiterated a “market perform” rating and issued a $1,077.00 price target (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,119.00.

Regeneron Pharmaceuticals Trading Down 1.3 %

Shares of REGN opened at $999.02 on Wednesday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $110.13 billion, a P/E ratio of 29.55, a price-to-earnings-growth ratio of 3.45 and a beta of 0.12. The stock’s fifty day simple moving average is $1,121.23 and its 200 day simple moving average is $1,038.27. Regeneron Pharmaceuticals has a twelve month low of $769.19 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The firm’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $8.79 EPS. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post 37.8 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Jason Pitofsky sold 487 shares of the business’s stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total transaction of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 487 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Sachetta LLC raised its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the period. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at $26,000. West Paces Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 575.0% during the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $28,000. Finally, Lynx Investment Advisory acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter worth $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.